Or,.t may be that the protein in the lens just changes from the wear and tear it takes over the years. Serious infection can result in loss of vision. Age-related cataract is associated with type 2 diabetes and satin use. Other tests are rarely needed, except to rule out other causes of poor vision. Gary heating, OD, and Judith Lee also contributed to this article. New glasses, brighter lighting, anti-glare sunglasses or magnifying lenses can help at first. It develops slowly and eventually interferes with your vision. A contact lens may not be a good choice for young children or older adults who have a hard time properly placing the lens on the eye .
The.OU is clear, unlike your natural lens that may have had a yellowish/brownish tint. The most common tonometry test uses a painless puff of air to flatten your cornea and test your eye pressure. This prevents light from passing clearly through the lens, causing some loss of vision . How will I know when to have cataract surgery? June 11, 2013. Secondary cataracts are caused by disease or medications. You and your surgeon will discuss which implant lens type and power is the right choice for you. It also is one of the safest and most effective types of surgery. A cataract can occur in either or both eyes. Cataracts can develop after an eye injury, sometimes years later. Cataracts can develop after exposure to some types of radiation. no dataBut if impaired vision interferes with your usual activities, you might need cataract surgery.
The three new cohorts in our Phase 1b/2a trial of the EGP-437 combination product in cataract surgery patients have progressed according to plan and we remain on track to report top-line data from these cohorts in the fourth quarter of 2016. We believe that these additional cohorts, which are evaluating additional doses and dosing regimens of EGP-437, will allow us to build upon the positive top-line data we reported in August and to initiate a randomized, placebo-controlled trial of EGP-437 in cataract surgery patients in the first quarter of 2017. In addition, patient enrollment in the confirmatory Phase 3 trial of the EGP-437 combination product in uveitis progressed, and the Company earned another milestone payment under our worldwide licensing agreement with Valeant for this indication. We continue to target an NDA submission for the EGP-437 combination product in uveitis in late 2017. A Background In No-fuss Strategies In Eye Bags | Savannah Owens TravelMr. From continued, We are extremely pleased with the progress we have made on the EGP-437 combination product, and have also taken important steps forward in the development of our CHMA-S platform and its lead product, the EyeGate OBG. We are on track for a meeting with the FDA and expect to initiate our first CMHA-S clinical trial, in corneal repair, by the end of the year. Additionally, we received the second year of funding of our Phase II SBIR grant from the U.S. Department of Defense to continue studying the use of CMHA-S as an ocular bandage film, which represents a large potential market. We are extremely excited about what the future holds for EyeGate and look forward to the opportunities that lie ahead. Third Quarter 2016 Financial Review EyeGates revenue for the third quarter of 2016 totaled $0.274 million, compared with no revenue in the third quarter of 2015.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/eyegate-pharmaceuticals-reports-third-quarter-132000500.html